Erratum: Expression of concern: “Tyrosine phosphatase inhibitors combined with retinoic acid can enhance differentiation of neuroblastoma cells and trigger ERK- and AKT-dependent, p53-independent senescence” (Cancer Letters (2013) 328(1) (44–54), (S0304383512005630), (10.1016/j.canlet.2012.09.014));Tyrosine phosphatase inhibitors combined with retinoic acid can enhance differentiation of neuroblastoma cells and trigger ERK- and AKT-dependent, p53-independent senescence

Cancer Letters

Volumn 328, Issue 1, 2013, Pages 44-54

  Clark, Owen ^a   Daga, Shruti ^a   Stoker, Andrew W ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Neuroblastoma; P53; PTEN; Senescence; Tyrosine phosphatase; Vanadium

Indexed keywords

EID: 84868466407     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2021.08.035     Document Type: Erratum

References (63)

1. Reynolds T. Differentiation therapy forces cancer cells to mature. J. Natl. Cancer Inst. 1991, 83:1209-1211.
2. Nardella C., Clohessy J.G., Alimonti A., Pandolfi P.P. Pro-senescence therapy for cancer treatment. Nat. Rev. Cancer 2011, 11:503-511.
3. Lin A.W., Barradas M., Stone J.C., Van Aelst L., Serrano M., Lowe S.W. Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev. 1998, 12:3008-3019.
4. Romagosa C., Simonetti S., Lopez-Vicente L., Mazo A., Lleonart M.E., Castellvi J., Ramon y Cajal S. p16(Ink4a) overexpression in cancer: a tumor suppressor gene associated with senescence and high-grade tumors. Oncogene 2011, 30:2087-2097.
5. Wu C.-H., van Riggelen J., Yetil A., Fan A.C., Bachireddy P., Felsher D.W. Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proc. Natl. Acad. Sci. USA 2007, 104:13028-13033.
6. Michaloglou C., Vredeveld L.C.W., Soengas M.S., Denoyelle C., Kuilman T., Van Der Horst C.M.A.M., Majoor D.M., Shay J.W., Mooi W.J., Peeper D.S. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 2005, 436:720-724.
7. Nogueira V., Park Y., Chen C.-C., Xu P.-Z., Chen M.-L., Tonic I., Unterman T., Hay N. Akt determines replicative senescence and oxidative or oncogenic premature senescence and sensitizes cells to oxidative apoptosis. Cancer Cell 2008, 14:458-470.
8. Lee J.-J., Kim B.C., Park M.-J., Lee Y.-S., Kim Y.-N., Lee B.L., Lee J.-S. PTEN status switches cell fate between premature senescence and apoptosis in glioma exposed to ionizing radiation. Cell Death Differ. 2011, 18:666-677.
9. Alimonti A., Nardella C., Chen Z., Clohessy J.G., Carracedo A., Trotman L.C., Cheng K., Varmeh S., Kozma S.C., Thomas G., Rosivatz E., Woscholski R., Cognetti F., Scher H.I., Pandolfi P.P. A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. J. Clin. Invest. 2010, 120:681-693.
10. Brodeur G.M. Neuroblastoma: biological insights into a clinical enigma. Nat. Rev. Cancer 2003, 3:203-216.
11. Sidell N., Altman A., Haussler M.R., Seeger R.C. Effects of retinoic acid (RA) on the growth and phenotypic expression of several human neuroblastoma cell lines. Exp. Cell Res. 1983, 148:21-30.
12. Bénard J., Raguénez G., Kauffmann A., Valent A., Ripoche H., Joulin V., Job B., Danglot G., Cantais S., Robert T., Terrier-Lacombe M.-J., Chassevent A., Koscielny S., Fischer M., Berthold F., Lipinski M., Tursz T., Dessen P., Lazar V., Valteau-Couanet D. MYCN-non-amplified metastatic neuroblastoma with good prognosis and spontaneous regression: a molecular portrait of stage 4S. Mol. Oncol. 2008, 2:261-271.
13. Matthay K.K., Reynolds C.P., Seeger R.C., Shimada H., Adkins E.S., Haas-Kogan D., Gerbing R.B., London W.B., Villablanca J.G. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J. Clin. Oncol. 2009, 27:1007-1013.
14. Maris J.M. Recent advances in neuroblastoma. N. Engl. J. Med. 2010, 362:2202-2211.
15. Encinas M., Iglesias M., Liu Y., Wang H., Muhaisen A., Ceña V., Gallego C., Comella J.X. Sequential treatment of SH-SY5Y cells with retinoic acid and brain-derived neurotrophic factor gives rise to fully differentiated, neurotrophic factor-dependent, human neuron-like cells. J. Neurochem. 2000, 75:991-1003.
16. Sidell N., Wada R., Han G., Chang B., Shack S., Moore T., Samid D. Phenylacetate synergizes with retinoic acid in inducing the differentiation of human neuroblastoma cells. Int. J. Cancer. J. Int. Cancer 1995, 60:507-514.
17. Chen L., Malcolm A.J., Wood K.M., Cole M., Variend S., Cullinane C., Pearson A.D.J., Lunec J., Tweddle D.A. P53 is nuclear and functional in both undifferentiated and differentiated neuroblastoma. Cell Cycle 2007, 6:2685-2696.
18. Tweddle D.A., Pearson A.D., Haber M., Norris M.D., Xue C., Flemming C., Lunec J. The p53 pathway and its inactivation in neuroblastoma. Cancer Lett. 2003, 197:93-98.
19. Beltinger C.P., White P.S., Sulman E.P., Maris J.M., Brodeur G.M. No CDKN2 mutations in neuroblastomas. Cancer Res. 1995, 55:2053-2055.
20. Van Maerken T., Rihani A., Dreidax D., De Clercq S., Yigit N., Marine J.-C., Westermann F., De Paepe A., Vandesompele J., Speleman F. Functional analysis of the p53 pathway in neuroblastoma cells using the small-molecule MDM2 antagonist nutlin-3. Mol. Cancer Ther. 2011.
21. Van Maerken T., Speleman F., Vermeulen J., Lambertz I., De Clercq S., De Smet E., Yigit N., Coppens V., Philippé J., De Paepe A., Marine J.-C., Vandesompele J. Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma. Cancer Res. 2006, 66:9646-9655.
22. Wainwright L.J., Lasorella A., Iavarone A. Distinct mechanisms of cell cycle arrest control the decision between differentiation and senescence in human neuroblastoma cells. Proc. Nat. Acad. Sci. USA 2001, 98:9396-9400.
23. Julien S.G., Dube N., Hardy S., Tremblay M.L. Inside the human cancer tyrosine phosphatome. Nat. Rev. Cancer 2011, 11:35-49.
24. Tonks N.K. Protein tyrosine phosphatases: from genes, to function, to disease. Nat. Rev. Mol. Cell Biol. 2006, 7:833-846.
25. Encinas M., Iglesias M., Llecha N., Comella J.X. Extracellular-regulated kinases and phosphatidylinositol 3-kinase are involved in brain-derived neurotrophic factor-mediated survival and neuritogenesis of the neuroblastoma cell line SH-SY5Y. J. Neurochem. 1999, 73:1409-1421.
26. López-Carballo G., Moreno L., Masiá S., Pérez P., Barettino D. Activation of the phosphatidylinositol 3-kinase/Akt signaling pathway by retinoic acid is required for neural differentiation of SH-SY5Y human neuroblastoma cells. J. Biol. Chem. 2002, 25297-25304.
27. Rogers M.V., Buensuceso C., Montague F., Mahadevan L. Vanadate stimulates differentiation and neurite outgrowth in rat pheochromocytoma PC12 cells and neurite extension in human neuroblastoma SH-SY5Y cells. Neuroscience 1994, 60:479-494.
28. Faure R., Vincent M., Dufour M., Shaver A., Posner B.I. Arrest at the G2/M transition of the cell cycle by protein-tyrosine phosphatase inhibition: studies on a neuronal and a glial cell line. J. Cell. Biochem. 1995, 59:389-401.
29. Dimri G.P., Lee X., Basile G., Acosta M., Scott G., Roskelley C., Medrano E.E., Linskens M., Rubelj I., Pereira-Smith O. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 1995, 92:9363-9367.
30. Clark O., Schmidt F., Coles C.H., Tchetchelnitski V., Stoker A.W. Functional analysis of the putative tumor suppressor PTPRD in neuroblastoma cells. Cancer Invest. 2012, 30:422-432.
31. Srivastava A.K., Mehdi M.Z. Insulino-mimetic and anti-diabetic effects of vanadium compounds. Diabet. Med. 2005, 22:2-13.
32. Thompson K.H., Lichter J., Lebel C., Scaife M.C., Mcneill J.H., Orvig C. Vanadium treatment of type 2 diabetes: a view to the future. J. Inorg. Biochem. 2009, 103:554-558.
33. Niles R.M. Signaling pathways in retinoid chemoprevention and treatment of cancer. Mutat. Res. 2004, 555:81-96.
34. Miloso M., Villa D., Crimi M., Galbiati S., Donzelli E., Nicolini G., Tredici G. Retinoic acid-induced neuritogenesis of human neuroblastoma SH-SY5Y cells is ERK independent and PKC dependent. J. Neurosci. Res. 2004, 75:241-252.
35. Nagai J., Yazawa T., Okudela K., Kigasawa H., Kitamura H., Osaka H. Retinoic acid induces neuroblastoma cell death by inhibiting proteasomal degradation of retinoic acid receptor alpha. Cancer Res. 2004, 64:7910-7917.
36. Helson L., Helson C. Human neuroblastoma cells and 13-cis-retinoic acid. J. Neurooncol. 1985, 3:39-41.
37. Thiele C.J., Reynolds C.P., Israel M.A. Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma. Nature 1985, 313:404-406.
38. Chesler L., Schlieve C., Goldenberg D.D., Kenney A., Kim G., McMillan A., Matthay K.K., Rowitch D., Weiss W.A. Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma. Cancer Res. 2006, 66:8139-8146.
39. Marshall C.J. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 1995, 80:179-185.
40. von Kriegsheim A., Baiocchi D., Birtwistle M., Sumpton D., Bienvenut W., Morrice N., Yamada K., Lamond A., Kalna G., Orton R., Gilbert D., Kolch W. Cell fate decisions are specified by the dynamic ERK interactome. Nat. Cell Biol. 2009, 11:1458-1464.
41. Denu J.M., Tanner K.G. Specific and reversible inactivation of protein tyrosine phosphatases by hydrogen peroxide: evidence for a sulfenic acid intermediate and implications for redox regulation. Biochemistry 1998, 37:5633-5642.
42. 2 regulates the activation of distinct MAPK pathways. Free Radical Biol. Med. 2002, 33:1121-1132.
43. Evangelou A.M. Vanadium in cancer treatment. Crit. Rev. Oncol. Hematol. 2002, 42:249-265.
44. Narita M., Nunez S., Heard E., Narita M., Lin A.W., Hearn S.A., Spector D.L., Hannon G.J., Lowe S.W. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 2003, 113:703-716.
45. Chen Z., Trotman L.C., Shaffer D., Lin H.-K., Dotan Z.A., Niki M., Koutcher J.A., Scher H.I., Ludwig T., Gerald W., Cordon-Cardo C., Pandolfi P.P. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005, 436:725-730.
46. Chesler L., Goldenberg D.D., Collins R., Grimmer M., Kim G.E., Tihan T., Nguyen K., Yakovenko S., Matthay K.K., Weiss W.A. Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction. Neoplasia (New York, NY) 2008, 10:1268-1274.
47. Ramaswamy S., Nakamura N., Vazquez F., Batt D.B., Perera S., Roberts T.M., Sellers W.R. Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci USA 1999, 96:2110-2115.
48. Muñoz J., Lázcoz P., Inda M.M., Nistal M., Pestaña A., Encío I.J., Castresana J.S. Homozygous deletion and expression of PTEN and DMBT1 in human primary neuroblastoma and cell lines. Int. J Cancer. J. Int. Cancer 2004, 109:673-679.
49. Salmena L., Carracedo A., Pandolfi P.P. Tenets of PTEN tumor suppression. Cell 2008, 133:403-414.
50. Rosivatz E., Matthews J.G., McDonald N.Q., Mulet X., Ho K.K., Lossi N., Schmid A.C., Mirabelli M., Pomeranz K.M., Erneux C., Lam E.W.-F., Vilar R., Woscholski R. A small molecule inhibitor for phosphatase and tensin homologue deleted on chromosome 10 (PTEN). ACS Chem. Biol. 2006, 1:780-790.
51. Mak L.H., Vilar R., Woscholski R. Characterisation of the PTEN inhibitor VO-OHpic. J. Chem. Biol. 2010, 3:157-163.
52. Zhang Y., Yang J.M. The impact of cellular senescence in cancer therapy: is it true or not?. Acta Pharmacol. Sin. 2011, 32:1199-1207.
53. Astle M.V., Hannan K.M., Ng P.Y., Lee R.S., George A.J., Hsu A.K., Haupt Y., Hannan R.D., Pearson R.B. AKT induces senescence in human cells via mTORC1 and p53 in the absence of DNA damage: implications for targeting mTOR during malignancy. Oncogene 2011.
54. Lin H.K., Chen Z., Wang G., Nardella C., Lee S.W., Chan C.H., Yang W.L., Wang J., Egia A., Nakayama K.I., Cordon-Cardo C., Teruya-Feldstein J., Pandolfi P.P. Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature 2010, 464:374-379.
55. Yun U.J., Park S.E., Shin D.Y. P41-Arc, a regulatory subunit of Arp2/3 complex, can induce premature senescence in the absence of p53 and Rb. Exp. Mol. Med. 2011, 43:389-392.
56. Zou X., Ray D., Aziyu A., Christov K., Boiko A.D., Gudkov A.V., Kiyokawa H. Cdk4 disruption renders primary mouse cells resistant to oncogenic transformation, leading to Arf/p53-independent senescence. Genes Dev. 2002, 16:2923-2934.
57. Bastien J., Rochette-Egly C. Nuclear retinoid receptors and the transcription of retinoid-target genes. Gene 2004, 328:1-16.
58. López-Carballo G., Moreno L., Masiá S., Pérez P., Barettino D. Activation of the phosphatidylinositol 3-kinase/Akt signaling pathway by retinoic acid is required for neural differentiation of SH-SY5Y human neuroblastoma cells. J. Biol. Chem. 2002, 277:25297-25304.
59. Ohashi E., Kogai T., Kagechika H., Brent G.A. Activation of the PI3 kinase pathway by retinoic acid mediates sodium/iodide symporter induction and iodide transport in MCF-7 breast cancer cells. Cancer Res. 2009, 69:3443-3450.
60. Wu J., Hansen J.M., Hao L., Taylor R.N., Sidell N. Retinoic acid stimulation of VEGF secretion from human endometrial stromal cells is mediated by production of reactive oxygen species. J. Physiol. 2011, 589:863-875.
61. Krejsa C.M., Nadler S.G., Esselstyn J.M., Kavanagh T.J., Ledbetter J.A., Schieven G.L. Role of oxidative stress in the action of vanadium phosphotyrosine phosphatase inhibitors. Redox independent activation of NF-kappaB. J. Biol. Chem. 1997, 272:11541-11549.
62. Scior T., Mack H.-G., García J.A.G., Koch W. Antidiabetic Bis-Maltolato-OxoVanadium(IV): conversion of inactive trans- to bioactive cis-BMOV for possible binding to target PTP-1B. Drug Des. Devel. Ther. 2009, 2:221-231.
63. Peters K.G., Davis M.G., Howard B.W., Pokross M., Rastogi V., Diven C., Greis K.D., Eby-Wilkens E., Maier M., Evdokimov A., Soper S., Genbauffe F. Mechanism of insulin sensitization by BMOV (bis maltolato oxo vanadium); unliganded vanadium (VO4) as the active component. J. Inorg. Biochem. 2003, 96:321-330.